BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative Frequency Of CVH Events Relative To Placebo At Month 30
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma presented data showing that their drug acoramidis significantly increases serum TTR levels and reduces cardiovascular events in ATTR-CM patients. The study demonstrated a 42% reduction in composite cardiovascular events and a 50% reduction in cardiovascular hospitalization frequency compared to placebo over 30 months.

August 30, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio's acoramidis shows significant efficacy in increasing serum TTR levels and reducing cardiovascular events in ATTR-CM patients, potentially boosting the company's stock.
The positive clinical trial results for acoramidis, showing significant reductions in cardiovascular events and hospitalizations, are likely to enhance investor confidence in BridgeBio's product pipeline, potentially leading to a positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100